The GSTP1 Ile(105)Val polymorphism is associated in a dose-dependent fashion with increased survival of patients with advanced colorectal cancer receiving 5-FU/oxaliplatin chemotherapy.
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
In conclusion, the meta-analysis suggests that the GSTP1 Ile105Val polymorphism is unlikely to increase considerably the risk of sporadic colorectal cancer, and it should be confirmed in further studies.
To determine whether genetic polymorphisms of GSTP1 Ile105Val (A-->G) predict chemosensitivity and clinical outcome in patients with advanced colorectal cancer, treated by 5-FU/oxaliplatin-based chemotherapy.